COVID Antibody Treatments Show Promise for Preventing Severe Disease

COVID Antibody Treatments Show Promise for Preventing Severe Disease

Two clinical trials suggest that specific antibody treatments can prevent deaths and hospitalizations among people with mild or moderate COVID-19—particularly those who are at high risk of developing severe disease. The study results, both announced on 10 March, come from randomized, placebo-controlled, double-blind clinical trials, but have not yet been published. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19. Earlier in the pandemic, some key clinical trials involving people who had been hospitalized with COVID-19 found no benefit from monoclonal antibodies. The speed with which these monoclonal antibodies were developed holds a lesson for future pandemics, says Khoo.

About Us

When you want to outsmart the world, you turn to the facts. And the facts are in the science.

Subscribe to our newsletter!